Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

NCT ID: NCT05554406

This clinical trial, called the MyeloMATCH Treatment Trial, is investigating different treatment options for adults who have recently been diagnosed with a serious form of blood cancer called high-...

Recruiting

Phase: PHASE2 Type: interventional Locations: Chicago, Illinois, United States, Durham, North Carolina, United States +187 more

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT ID: NCT05564390

The MYELOMATCH trial is a research study designed to help people with certain types of blood cancers, specifically acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The main goal of ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Chicago, Illinois, United States, Durham, North Carolina, United States +310 more

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

NCT ID: NCT04256317

This clinical trial is studying a new treatment called ASTX030, which combines two medications, cedazuridine and azacitidine, to see how well they work for patients with certain blood disorders, in...

Recruiting

Phase: PHASE2 Type: interventional Locations: New Haven, Connecticut, United States, Rochester, New York, United States +28 more

Testing the Addition of an IDH1 Inhibitor, Olutasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH1 Mutation (A MyeloMATCH Treatment Trial)

NCT ID: NCT07153497

This clinical trial is testing whether adding a new medicine called olutasidenib to the usual treatment can help people with a type of blood disorder called higher-risk myelodysplastic syndrome (MD...

Not yet recruiting

Phase: PHASE2 Type: interventional

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

NCT ID: NCT05554393

This clinical trial, called the MyeloMATCH Treatment Trial, is studying different treatment combinations for younger patients with a type of blood cancer known as acute myeloid leukemia (AML). The ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Chicago, Illinois, United States, Durham, North Carolina, United States +158 more

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT ID: NCT04065399

This clinical trial is studying a new medication called revumenib for patients with various types of acute leukemia, including those with specific genetic changes. The trial has two phases: the fir...

Recruiting

Phase: PHASE1 Type: interventional Locations: Columbus, Ohio, United States, Philadelphia, Pennsylvania, United States +62 more

National Cancer Institute "Cancer Moonshot Biobank"

NCT ID: NCT04314401

The "Cancer Moonshot Biobank" is a clinical trial that aims to gather blood and tissue samples from patients diagnosed with various types of cancer, including advanced stages of breast cancer, lung...

Recruiting

Type: observational Locations: Des Moines, Iowa, United States, Scarborough, Maine, United States +181 more

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

NCT ID: NCT06954987

This clinical trial, called the MyeloMATCH treatment trial, is studying whether adding a medication called venetoclax to a specific type of chemotherapy can improve treatment outcomes for patients ...

Not yet recruiting

Phase: PHASE2 Type: interventional

Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

NCT ID: NCT07044687

This clinical trial is studying a new treatment option for adults in India who have been newly diagnosed with acute myeloid leukemia (AML), a serious type of blood cancer. The study is looking at h...

Recruiting

Phase: PHASE4 Type: interventional Locations: Pune, Maharashtra, India, Hyderabad, Telangana, India +1 more

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

NCT ID: NCT06317649

This clinical trial is studying how effective a combination of three drugs—azacitidine, venetoclax, and gilteritinib—might be for older adults who have a specific type of blood cancer called acute ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Chicago, Illinois, United States, New Haven, Connecticut, United States +201 more

A Study of BGB-11417 in Participants With Myeloid Malignancies

NCT ID: NCT04771130

This clinical trial is studying a new drug called BGB-11417 to see how safe it is, how well it works, and what the best dose is for treating certain blood cancers, specifically Acute Myeloid Leukem...

Recruiting

Phase: PHASE1 Type: interventional Locations: Milwaukee, Wisconsin, United States, Duarte, California, United States +103 more

Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological Malignancies

NCT ID: NCT07147621

This clinical trial is studying how chemotherapy treatment for blood cancers—like acute myeloid leukemia, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma—might affect thinking skills such as memory,...

Not yet recruiting

Type: observational

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML (RADAR)

NCT ID: NCT07157514

This trial is testing a new way to prepare the body for an allogeneic stem cell transplant in adults with relapsed or refractory acute myeloid leukemia (AML). In Phase 2, researchers will test thre...

Not yet recruiting

Phase: PHASE2 Type: interventional

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

NCT ID: NCT05554419

The ERASE Study is a clinical trial designed to explore different combinations of treatments for patients with persistent low-level Acute Myeloid Leukemia (AML) after their initial therapy. The tri...

Not yet recruiting

Phase: PHASE2 Type: interventional

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

NCT ID: NCT06456463

This clinical trial is studying a new treatment approach for adults with a type of blood cancer called acute myeloid leukemia (AML) who cannot undergo standard intensive chemotherapy. The treatment...

Recruiting

Phase: PHASE2 Type: interventional Locations: Boston, Massachusetts, United States, Los Angeles, California, United States +42 more

Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia

NCT ID: NCT07146542

This clinical trial is studying a protein called CD81 and how it might affect certain types of blood cancer called myeloid leukemia, including acute myeloid leukemia (AML) and chronic myeloid leuke...

Not yet recruiting

Type: observational

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

NCT ID: NCT06969430

This clinical trial is testing a new treatment called Debio 1562M for patients with a type of cancer called Acute Myeloid Leukemia (AML). The trial is divided into two phases. In the first phase, r...

Recruiting

Phase: PHASE1 Type: interventional Locations: Chicago, Illinois, United States, Duarte, California, United States +5 more

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

NCT ID: NCT06389292

This clinical trial is studying a new treatment option for patients with acute myeloid leukemia (AML), a type of blood cancer. Specifically, the trial is looking at a medication called APG-2575 (al...

Recruiting

Phase: PHASE3 Type: interventional Locations: Saint Petersburg, Russian Federation, Hangzhou, Zhejiang, China +4 more

A Study of GLB-001 in Patients With Myeloid Malignancies

NCT ID: NCT06378437

This clinical trial, called GLB-001-02, is investigating a new treatment called GLB-001 for patients with certain blood cancers known as myeloid malignancies. These include conditions like polycyth...

Recruiting

Phase: PHASE1 Type: interventional Locations: Chongqing, Chongqing, China, Beijing, Beijing, China +14 more

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

NCT ID: NCT06802523

This clinical trial is investigating a new treatment approach for adults with newly diagnosed acute myeloid leukemia (AML), a type of blood cancer. The study will test the safety and effectiveness ...

Recruiting

Phase: PHASE1 Type: interventional Locations: New Haven, Connecticut, United States

Main Menu

Clinical Trials for Acute Myeloid Leukemia

353 Active Trials Found

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Testing the Addition of an IDH1 Inhibitor, Olutasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH1 Mutation (A MyeloMATCH Treatment Trial)

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

National Cancer Institute "Cancer Moonshot Biobank"

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

A Study of BGB-11417 in Participants With Myeloid Malignancies

Evaluation of Chemotherapy-induced Cognitive Disorders During the Treatment of Hematological Malignancies

Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML (RADAR)

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Expression Pattern and Possible Clinical Significance of CD81 In Myeloid Leukemia

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

A Study of GLB-001 in Patients With Myeloid Malignancies

Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia

Related Conditions